Work

Navigating a Paradigm Shift: Lerodalcibep in Patients with Cardiovascular Diseases as an Alternative to Monoclonal Antibodies (PCSK9 Inhibitors)

Year: 2024

Type: article

Abstract: Nearly 17.5 million deaths globally are attributed to non-communicable disease (NCD) causes, with cardiovascular disease (CVD) being the main culprit. Low-density lipoprotein cholesterol (LDL-C) medications are now available, but cardiovascular disease (CVD) still causes a considerable amount of morbidity and mortality, especially in patients who may not respond well to existing treatments. In this regard, significant progress has been made in reducing LDL-C levels and, consequently, the risk of CVD with monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9). Even with these medications, more easily available, reasonably priced, and patient-friendly substitutes are still required.

Source: Journal of Science Technology Education Art and Medicine

DOI: 10.63137/jsteam.987143

Authors: Muhammad Nouman Javed, Syed Muhammad Ali

Institution: Hamad Medical Corporation

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4407785321